Literature DB >> 21297650

Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.

Massimo Filippi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21297650     DOI： 10.1038/nrneurol.2010.215

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group.

Authors:  Sheila A Doggrell
Journal:  Expert Opin Pharmacother       Date:  2010-05       Impact factor: 3.889

2.  Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.

Authors:  Laura F van der Voort; Francesca Gilli; Antonio Bertolotto; Dirk L Knol; Bernard M J Uitdehaag; Chris H Polman; Joep Killestein
Journal:  Arch Neurol       Date:  2010-02-08

3.  Complement regulator factor H as a serum biomarker of multiple sclerosis disease state.

Authors:  Gillian Ingram; Svetlana Hakobyan; Claire L Hirst; Claire L Harris; Trevor P Pickersgill; Mark D Cossburn; Sam Loveless; Neil P Robertson; Bryan Paul Morgan
Journal:  Brain       Date:  2010-04-25       Impact factor: 13.501

4.  Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D S Goodin; E M Frohman; B Hurwitz; P W O'Connor; J J Oger; A T Reder; J C Stevens
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

5.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Authors:  Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  MRI criteria for MS in patients with clinically isolated syndromes.

Authors:  X Montalban; M Tintoré; J Swanton; F Barkhof; F Fazekas; M Filippi; J Frederiksen; L Kappos; J Palace; C Polman; M Rovaris; N de Stefano; A Thompson; T Yousry; A Rovira; D H Miller
Journal:  Neurology       Date:  2010-01-06       Impact factor: 9.910

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422
  10 in total
  2 in total

1.  MicroRNA expression aberration in Chinese patients with relapsing remitting multiple sclerosis.

Authors:  Dan Yang; Wei-Zhi Wang; Xue-Mei Zhang; Hui Yue; Bing Li; Lin Lin; Jin Fu
Journal:  J Mol Neurosci       Date:  2013-11-12       Impact factor: 3.444

2.  Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis.

Authors:  Hanni S M Kiiski; Sinéad Ní Riada; Edmund C Lalor; Nuno R Gonçalves; Hugh Nolan; Robert Whelan; Róisín Lonergan; Siobhán Kelly; Marie Claire O'Brien; Katie Kinsella; Jessica Bramham; Teresa Burke; Seán Ó Donnchadha; Michael Hutchinson; Niall Tubridy; Richard B Reilly
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.